ACELYRIN, Inc. has announced its confidence in a proposed merger with Alumis Inc., scheduled for a stockholder vote on May 13, 2025. The merger aims to create a leading clinical-stage immunology company with a diversified portfolio of product candidates. ACELYRIN's Board of Directors emphasizes that the merger represents the culmination of a comprehensive and competitive process designed to maximize value for all stockholders. ACELYRIN stockholders are expected to retain approximately 48% ownership in the combined company, providing them with significant potential upside. The Board encourages stockholders to focus on the long-term benefits of the merger.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。